Logo
S

SHANDONG QILU MEDICINES IMP. EXP.

山东齐鲁医药进出口有限公司,成立于2001年,位于山东省济南市,是一家以从事商务服务业为主的企业。企业注册资本120000万人民币,实缴资本89950万人民币。
Country/AreaChina
Industry批发和零售业/批发业Safety and SecurityElectronicsManufacturing GeneralManufacturing
Company website
Company phone+86 53183127705
Established1958
Company Revenue$7,228,000
Number of employees<25
SIC Code28283
NAICS Code32325
Main Products抗肿瘤用药 SEE MORE眼科用药 SEE MORE齐鲁镜界 Videos 点击进入心脑血管用药 SEE MORE集团公告 Group Announcement 点击进入男科用药 SEE MORE精神药物 SEE MORE网站建设:中企动力 济南神经系统用药 SEE MORE抗感染用药 SEE MORE其他用药 SEE MORE视觉齐鲁 Images 点击进入
https://www.linkedin.com/company/qilupharmaceuticalshttps://twitter.com/qilupharmanews

Company News

QiLu Pharmaceutical's Iruplinalkib Phase III INSPIRE Study Researched Primary Endpoint and was Selected for 2023 WCLC Oral Presentation
JINAN, China, Aug. 17, 2023 /PRNewswire/ -- August 16, 2023, at the 2023 World Conference on Lung Cancer (WCLC), the complete list of selected abstracts was announced, among which QiLu Pharmaceutical's iruplinalkib phase III clinical trial (INSPIRE) results were chosen for oral...
dateAug 18, 2023
Chinese Company Qilu Pharmaceutical Is Supplying the Anti-Cancer Drug Cisplatin Injection to the United States Again
Qingdao, China--(Newsfile Corp. - July 2, 2023) - On June 30th Beijing time, Qilu Pharmaceutical Group, located in Shandong Province, China, will export more than 45000 cisplatin injections produced to the United States. This is the second batch of drugs supplied by this well-known Chinese pharmaceutical company to the United States, following the first batch of 18000 cisplatin injections exported to the United States. Chinese company Qilu Pharmaceutical is supplying the anti-cancer drug...
CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop "Off-the-Shelf" CAR-iMAC Cell Therapy
HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- CellOrigin Biotech (Hangzhou) Co., Ltd. announced it has made a global strategic collaboration agreement with Qilu Pharma to develop, manufacture and commercialize proprietary "off-the-shelf" induced pluripotent stem cell- (iPSC) derived...
dateSep 26, 2022
CellOrigin Biotech announced strategic global collaboration with Qilu Pharmaceutical to develop "off-the-shelf" CAR-iMAC cell therapy
HANGZHOU, China, Sept. 5, 2022 /PRNewswire/ -- CellOrigin Biotech (Hangzhou) Co., Ltd. announced that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary "off-the-shelf" iPSC-derived Chimeric Antigen...
Qilu Pharmaceutical to present 4 posters at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
CHICAGO, ILLINOIS, UNITED STATES, June 1, 2022 /⁨EINPresswire.com⁩/ -- Qilu Pharmaceutical will be presenting four of its pipeline products at the Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held on June 3-7, 2022 in Chicago, …

Web Summary

Q1: What is the address of Shandong Qilu Medicine Import and Export Co., Ltd.?
A1: The address of Shandong Qilu Medicine Import and Export Co., Ltd. is located at No. 8888, Tourist Road, High-Technology Zone, Jinan, Shandong Province, China.

Q2: What types of products does Shandong Qilu Medicine Import and Export Co., Ltd. offer?
A2: The company offers a wide range of products, including anti-tumor medications, nervous system medications, cardiovascular medications, psychiatric medications, antibacterial medications, urological medications, ophthalmological medications, and other medications.

Q3: What is the industry that Shandong Qilu Medicine Import and Export Co., Ltd. operates in?
A3: The company operates in the pharmaceutical industry, specifically in the development, production, and import/export of medicinal products.

Q4: What services does Shandong Qilu Medicine Import and Export Co., Ltd. provide?
A4: The company provides various services, including business consulting, product sales, marketing, and after-sales service.

Q5: How can one contact Shandong Qilu Medicine Import and Export Co., Ltd. for business inquiries or other purposes?
A5: One can contact the company through their official website, phone numbers (0531-83126666/7777/8888/9999), email address (wangzhan@qilu-pharma.com), or by visiting their office located at No. 8888, Tourist Road, High-Technology Zone, Jinan, Shandong Province, China.

Q6: What is the name of the subsidiary company of Shandong Qilu Medicine Import and Export Co., Ltd.?
A6: The subsidiary companies of Shandong Qilu Medicine Import and Export Co., Ltd. include Qilu Pharmaceutical Co., Ltd., Qilu Pharmaceutical Sales Corporation, Qilu Anrele Pharmaceutical Co., Ltd., Dongying Anxin Pharmaceutical Co., Ltd., Qilu Pharmaceutical (Inner Mongolia) Co., Ltd., Qilu Pharmaceutical (Hainan) Co., Ltd., Dongying Hongrong Pharmaceutical Co., Ltd., and others.

Q7: What is the name of the research institute established by Shandong Qilu Medicine Import and Export Co., Ltd.?
A7: The research institute established by Shandong Qilu Medicine Import and Export Co., Ltd. is called the Qilu Pharmaceutical Research Institute (now known as the Qilu Pharmaceutical Research Institute).

Q8: What is the name of the first anti-tumor medication developed by Shandong Qilu Medicine Import and Export Co., Ltd.?
A8: The first anti-tumor medication developed by Shandong Qilu Medicine Import and Export Co., Ltd. is called "吉非替尼片" (Jifenipant), which was approved for marketing in 2016 and became the first non-small cell lung cancer targeted therapy drug in China.

Q9: What is the name of the oral anticoagulant medication developed by Shandong Qilu Medicine Import and Export Co., Ltd.?
A9: The oral anticoagulant medication developed by Shandong Qilu Medicine Import and Export Co., Ltd. is called "甲苯磺酸艾多沙班片" (Tisarogabat), which was approved for marketing in 2025.

Q10: What is the purpose of the anti-coagulant medication developed by Shandong Qilu Medicine Import and Export Co., Ltd.?
A10: The anti-coagulant medication developed by Shandong Qilu Medicine Import and Export Co., Ltd. is used to prevent stroke and thrombosis in patients with one or more risk factors for cardiovascular disease, as well as to treat deep vein thrombosis and pulmonary embolism, and to prevent the recurrence of these conditions.
Customs Data
As a purchaser
As a Supplier
Disable_icon
Get the Whole details
DisableData_png
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Disable_icon
Get the Whole details
DisableContact_png